pharmaphorum
@pharmaphorum.bsky.social
pharmaphorum.com, and its magazine Deep Dive, is a leading online destination for pharmaceutical industry and healthcare news, insight, and debate
Some #pharmacists in #England can now #prescribe medicines for #acne, #migraines, #scabies, #earinfections, and #rhinitis in a major expansion of the #PharmacyFirst scheme first introduced in 2024. pharmaphorum.com/news/five-in...
There's been talk about forging closer ties between #Europe and #Canada in response to the US' aggressive disruption of #internationaltrade. Now, two senior figures in Canada's #lifesciences sector have said they see scope for greater #collaboration with the #UK. pharmaphorum.com/news/could-u...
Could UK clinical trial revamp unlock closer ties with Canada?
Two senior figures in Canada's life science sector have said they see scope for greater collaboration with the UK following clinical trial reforms.
pharmaphorum.com
#Patients with a #rare #autoimmunedisease known as #MOGAD could be just a few months away from having the first approved treatment. buff.ly/7T2BYQF
Reviews underway of first drug for rare disease MOGAD
Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.
pharmaphorum.com
#Bayer has won #FDAapproval for #oralHER2inhibitor #Hyrnuo as a #firstlinetreatment for advanced HER2-mutant non-small cell lung cancer (#NSCLC), just a year after it was cleared as a second-line option. pharmaphorum.com/news/bayer-m...
Bayer moves Hyrnuo into frontline lung cancer treatment
Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
pharmaphorum.com
#Gilead's twice-yearly #injectable for pre-exposure prophylaxis (#PrEP) of #HIV, #lenacapavir, will not be routinely funded by the NHS, according to initial draft guidance from reimbursement authority #NICE. pharmaphorum.com/news/nice-sa...
NICE says no to Gilead's lenacapavir for HIV PrEP
NICE's decision not to recommend NHS funding of Gilead's twice-yearly injectable for prevention of HIV has drawn fierce criticism from charities.
pharmaphorum.com
#Amgen's fast-growing cancer #immunotherapy #Imdelltra could move into the first-line setting in #smallcelllungcancer (SCLC), after delivering as a #dualregimen with AstraZeneca's Imfinzi in the DeLLphi-305 study. pharmaphorum.com/news/amgens-...
Amgen's Imdelltra scores again in small cell lung cancer
Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.
pharmaphorum.com
#BristolMyersSquibb's GPRC5D-directed #CARTtherapy, arlocabtagene autoleucel (#arlocel), has shown activity in a phase 2 trial that could underpin future filings for #bloodcancer #multiplemyeloma. pharmaphorum.com/news/bms-eye...
BMS eyes role for new CAR-T in post-BCMA multiple myeloma
BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.
pharmaphorum.com
The #FDA has started a #priorityreview of #AstraZeneca's IL-33-targeting antibody #tozorakimab for chronic obstructive pulmonary disease (#COPD), setting up a decision on the would-be blockbuster in the first quarter of 2027. pharmaphorum.com/news/fda-sta...
#HHS has moved to firm up the #leadership at the #FDA after a long period of uncertainty and disruption, upgrading the heads of the agency's centres governing drugs and biologics from acting to #permanent status. pharmaphorum.com/news/fda-mak...
FDA makes acting CDER, CBER chiefs permanent
Michael Davis becomes the permanent head of CDER, while Karim Mikhail is confirmed as permanent CBER director and the FDA names its first AI leader.
pharmaphorum.com
An #AI-powered #imaging tool developed by #Brainomix has been used to enrich data from a phase 2a trial of #EndeavorBioMedicines' hedgehog pathway inhibitor #taladegib, in development for #idiopathicpulmonaryfibrosis (IPF). pharmaphorum.com/news/brainom...
Brainomix AI lends weight to Endeavor Bio's IPF trial data
An AI-based imaging tool from Brainomix has been used to enrich data from a phase 2a trial of Endeavor's idiopathic pulmonary fibrosis drug taladegib.
pharmaphorum.com
Swiss biotech #Pharvaris has reported positive data from a phase 3 trial of its drug for #hereditaryangioedema (HAE), setting up #marketingapplications next year. pharmaphorum.com/news/pharvar...
Pharvaris plans filings for HAE drug after pivotal trial win
Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.
pharmaphorum.com
#Sandoz has told #investors that it intends to double its #netsales between 2025 and 2035, and sees a pivot towards #biosimilars as the driving force for that growth. buff.ly/htHVive
Sandoz says it is entering "golden decade" in biosimilars
Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.
pharmaphorum.com
There's no underplaying the seriousness of #chronicobstructivepulmonarydisease (COPD), the third leading cause of death worldwide, but a new study suggests #laughter may be the right response. pharmaphorum.com/news/it-turn...
It turns out COPD may be a laughing matter after all
Researchers in Türkiye have shown in a small clinical trial that laughter therapy can reduce breathing difficulties in COPD patients.
pharmaphorum.com
Hard on the heels of a big #disappointment in its cardiovascular pipeline, #Novartis has suffered another – this time for its highly anticipated #neuromusculardisease therapy #deldesiran. pharmaphorum.com/news/novarti...
Novartis falls sharply on another major R&D setback
Novartis has suffered another pipeline blow, this time involving its highly anticipated neuromuscular disease therapy del-desiran.
pharmaphorum.com
The #UK is starting to benefit from a "real #partnership" between the #pharmaindustry and #government that is reversing years of diminishing #investment, but more must be done to secure the gains. pharmaphorum.com/news/pharma-...
Pharma body sees 'green shoots' in UK investment
The UK is starting to benefit from a "real partnership" between pharma and government, reversing years of diminishing investment, says the ABPI.
pharmaphorum.com
London-based #ClaretCapitalPartners has closed its fourth #EuropeanGrowthCapitalFund, raising €575 million ($668 million), which will be used to "back #Europe's boldest innovators." pharmaphorum.com/news/uks-cla...
UK's Claret Capital raises €575m for European biotechs
London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575m for "Europe's boldest innovators."
pharmaphorum.com
#NovoNordisk has opted to discontinue two late-stage trials of IL-6 inhibitor #ziltivekimab in #heartfailure, after an interim look at the data suggested they would be unlikely to show a positive result. pharmaphorum.com/news/novo-no...
#Novartis shares dipped lower this morning after the company revealed its Lp(a)-targeted drug, #pelacarsen, failed to reduce #cardiovascular risks in a major phase 3 trial. pharmaphorum.com/news/novarti...
The #FDA has gone against the advice of its own expert advisors and approved #AstraZeneca's #Etcamah as a frontline treatment for #breastcancer. pharmaphorum.com/news/fda-ove...
An #NHS trust in the #UK has become the first site in #Europe to offer #Roche's experimental drug #trontinemab to patients enrolled in a large-scale #trial to see if it can delay or #prevent #Alzheimersdisease. pharmaphorum.com/news/major-t...
Major trial of Roche Alzheimer's drug kicks off in Europe
The PrevenTRON trial of Roche's Brainshuttle drug trontinemab in preclinical Alzheimer's disease has gotten underway in the UK.
pharmaphorum.com
#Merck KGaA's recently approved #neurofibromatosistype1 (NF1) therapy #Ezmekly has been cleared for routine #NHS use in #England, becoming an option for #children as young as two with the #raredisease. pharmaphorum.com/news/merck-r...
Merck rare tumour drug Ezmekly backed for NHS use
Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
pharmaphorum.com
A #kidney transplanted into a #human patient from a genetically modified #pig has broken records by lasting for around nine months, buying time until a human #donor #organ became available. pharmaphorum.com/news/pig-hum...
Pig to human kidney transplantation hits a new milestone
A pig kidney transplanted into a human patient has broken records by lasting for nine months, buying time until a human donor organ became available.
pharmaphorum.com
In another example of the impact of #climatechange on #publichealth, invasive #Aedesaegypti #mosquitoes and their larvae have been discovered at residential properties in #London. pharmaphorum.com/news/viral-d...
#AbbVie has reported positive results with #Tcellengager etentamig in relapsed or refractory #multiplemyeloma, a key programme in the company's expansion into the #oncology sector. pharmaphorum.com/news/abbvies...
AbbVie's cancer TCE etentamig hits the mark in myeloma
AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?
pharmaphorum.com
#Ionis' antisense therapy #Zanvastro has been approved by the #FDA for #Alexanderdisease (AxD), throwing a lifeline to people living with the rare and devastating #neurologicaldisorder. pharmaphorum.com/news/ionis-c...
Ionis claims first approval for Alexander disease therapy
Ionis' Zanvastro has been approved by the FDA for Alexander disease, becoming the first disease-modifying therapy for the devastating rare disease.
pharmaphorum.com